These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17925883)

  • 41. Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.
    Teicher MH; Polcari A; Foley M; Valente E; McGreenery CE; Chang WW; McKay G; Midha KK
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):416-31. PubMed ID: 16958567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and clinical effectiveness of methylphenidate.
    Kimko HC; Cross JT; Abernethy DR
    Clin Pharmacokinet; 1999 Dec; 37(6):457-70. PubMed ID: 10628897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aptensio XR--another long-acting methylphenidate.
    Med Lett Drugs Ther; 2015 Jul; 57(1473):101-3. PubMed ID: 26204039
    [No Abstract]   [Full Text] [Related]  

  • 44. Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences.
    Lloyd A; Hodgkins P; Dewilde S; Sasané R; Falconer S; Sonuga Barke E
    Int J Technol Assess Health Care; 2011 Jul; 27(3):215-23. PubMed ID: 21736859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders].
    Aanonsen NO
    Tidsskr Nor Laegeforen; 1999 Nov; 119(27):4040-2. PubMed ID: 10613094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
    Childress AC; Sallee FR; Berry SA
    Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methylphenidate: abuse and addiction.
    Prescrire Int; 2012 Oct; 21(131):241. PubMed ID: 23189380
    [No Abstract]   [Full Text] [Related]  

  • 48. Focalin XR for ADHD.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):22-4. PubMed ID: 19305368
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
    Arnold LE; Lindsay RL; Conners CK; Wigal SB; Levine AJ; Johnson DE; West SA; Sangal RB; Bohan TP; Zeldis JB
    J Child Adolesc Psychopharmacol; 2004; 14(4):542-54. PubMed ID: 15662146
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder.
    Teuscher NS; Adjei A; Findling RL; Greenhill LL; Kupper RJ; Wigal S
    Drug Des Devel Ther; 2015; 9():2767-75. PubMed ID: 26060393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies.
    Santos K; Palmini A; Radziuk AL; Rotert R; Bastos F; Booij L; Fernandes BS
    Dev Med Child Neurol; 2013 Jul; 55(7):654-60. PubMed ID: 23480530
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
    Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Flawed attention-deficit/hyperactivity disorder medication comparison.
    Adesman A
    Pediatrics; 2004 Oct; 114(4):1132; author reply 1132-3. PubMed ID: 15466129
    [No Abstract]   [Full Text] [Related]  

  • 56. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control.
    Sonuga-Barke EJ; Coghill D; Wigal T; DeBacker M; Swanson J
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):683-90. PubMed ID: 20035586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'.
    Olders H
    J Pediatr Psychol; 2009; 34(1):108-9; author reply 110-2. PubMed ID: 19136567
    [No Abstract]   [Full Text] [Related]  

  • 60. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
    Gau SS; Shen HY; Soong WT; Gau CS
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.